Fineline Cube

Follow:
14486 Articles
Huadong Medicine's Biosimilar Tresiba Accepted by NMPA for Review
CompanyDrug

Huadong Medicine’s Biosimilar Tresiba Accepted by NMPA for Review

Stabilizing Foreign Investment: China's Comprehensive Action Plan for 2025
Policy / Regulatory

Stabilizing Foreign Investment: China’s Comprehensive Action Plan for 2025

Nona Biosciences Licenses H2L2 Harbour Mice Platform to UAB for B Cell Research
CompanyDeals

Nona Biosciences Licenses H2L2 Harbour Mice Platform to UAB for B Cell Research

Innogen Pharmaceutical Launches Efsubaglutide Alfa for Type 2 Diabetes in China
CompanyDrug

Innogen Pharmaceutical Launches Efsubaglutide Alfa for Type 2 Diabetes in China

Bayer's AskBio Receives RMAT Designation for AB-1005 in Parkinson's Disease
CompanyDrug

Bayer’s AskBio Receives RMAT Designation for AB-1005 in Parkinson’s Disease

Phanes Therapeutics Doses First Patient in Peluntamig Study for SCLC and NEC
CompanyDrug

Phanes Therapeutics Doses First Patient in Peluntamig Study for SCLC and NEC

Epitopea and Merck Partner to Identify Cryptigen Tumor Antigens
CompanyDeals

Epitopea and Merck Partner to Identify Cryptigen Tumor Antigens

Boehringer Ingelheim's Zongertinib NDA Accepted by FDA for HER2-Mutated NSCLC
CompanyDrug

Boehringer Ingelheim’s Zongertinib NDA Accepted by FDA for HER2-Mutated NSCLC

Hepalink Pharmaceutical's H1710 Heparanase Inhibitor Approved for Phase I Study
CompanyDrug

Hepalink Pharmaceutical’s H1710 Heparanase Inhibitor Approved for Phase I Study

Henlius Biotech's Avastin Biosimilar Hanbeitai Approved in Bolivia
CompanyDrug

Henlius Biotech’s Avastin Biosimilar Hanbeitai Approved in Bolivia

Astellas Pharma's Xospata Wins Regular NMPA Approval for FLT3-Mutated AML
CompanyDrug

Astellas Pharma’s Xospata Wins Regular NMPA Approval for FLT3-Mutated AML

Hanx Biopharmaceuticals' HX009 Receives NMPA Clearance for TNBC Study
CompanyDrug

Hanx Biopharmaceuticals’ HX009 Receives NMPA Clearance for TNBC Study